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Abstract
Tumourigenesis within the intestine is potently driven by deregulation of the Wnt pathway, a process epigenetically
regulated by the chromatin remodelling factor Brg1. We aimed to investigate this interdependency in an in vivo setting and
assess the viability of Brg1 as a potential therapeutic target. Using a range of transgenic approaches, we deleted Brg1 in the
context of Wnt-activated murine small intestinal epithelium. Pan-epithelial loss of Brg1 using VillinCreERT2 and AhCreERT
transgenes attenuated expression of Wnt target genes, including a subset of stem cell-specific genes and suppressed Wnt-
driven tumourigenesis improving animal survival. A similar increase in survival was observed when Wnt activation and Brg1
loss were restricted to the Lgr5 expressing intestinal stem cell population. We propose a mechanism whereby Brg1 function
is required for aberrant Wnt signalling and ultimately for the maintenance of the tumour initiating cell compartment, such
that loss of Brg1 in an Apc-deficient context suppresses adenoma formation. Our results highlight potential therapeutic
value of targeting Brg1 and serve as a proof of concept that targeting the cells of origin of cancer may be of therapeutic
relevance.
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Introduction
More than 90% of colorectal cancers (CRC) are characterised
by aberrant activation of the canonical Wnt/b-catenin pathway,
which is proposed to play a major role in the initiation and
progression of CRC [1]. Despite this clear link between
deregulated Wnt signalling and disease, therapies which target
the Wnt pathway remain limited [2]. There is, therefore, a
substantial demand for novel approaches to inhibit the Wnt
pathway, preferably downstream of common aberrations such as
mutations in APC, AXIN2 or b-catenin. The emerging plethora of
epigenetic factors involved in DNA methylation, histone modifi-
cations and chromatin remodelling represent a set of new and
relatively unexplored opportunities for such therapeutic interven-
tion [3].
Brahma-related gene 1 (BRG1) or SWI/SNF-related matrix-associated
actin- dependent regulator of chromatin subfamily A member 4 (SMARCA4)
is one of the two mutually exclusive ATPase subunits of the 2-MD
family of SWItch/Sucrose Non-Fermentable (SWI/SNF) class of
chromatin remodelling complexes. BRG1 has been implicated in a
variety of biological processes, in both normal and neoplastic tissues
[4,5]. The majority of these studies, both in vitro and in vivo, suggest that
BRG1 acts as a tumour suppressor. For example, it has been found to
be mutated in numerous cancer cell lines and primary cancers [6–9].
In support of this, studies using Brg1 knock-out mouse models have
shown that heterozygous loss of Brg1 increases susceptibility to both
mammary gland and lung tumourigenesis [10,11].
By contrast, BRG1 has been shown to interact with b-catenin and
facilitate trans-activation of Wnt-dependent reporter assays and
endogenous Wnt target genes in cancer cell lines [12,13]. Therefore
better understanding of the role of BRG1 in aberrant Wnt signalling
may allow the development of novel Wnt intervention strategies.
We have recently reported that loss of Brg1 in the small
intestinal epithelium results in depletion of the intestinal stem cell
population [14]. In this study we aimed to investigate the
functional interaction between Brg1 and the Wnt pathway by
generating mice, which carried floxed alleles of both Apc [15] and
Brg1 [16,17] genes, thus placing Brg1 deficiency in the context of
aberrant activation of the Wnt pathway.
Using three different conditional approaches, we find that
additional loss of Brg1 from the small intestinal epithelium attenuates
the Wnt-dependent phenotype resulting from Apc deletion.
Results
Brg1 loss attenuates aberrant Wnt signalling in the
murine small intestinal epithelium
In order to assess the immediate consequences of Brg1 loss
upon Wnt activation, we employed the (Tg(Vil-cre/ESR1)23Syr)
transgene [18] driving expression of Cre-ERT2 recombinase under
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control of the Villin 1 promoter, further abbreviated as
VillinCreERT2. To achieve high penetrance inactivation of targeted
genes, VillinCreERT2+Apcfl/fl and VillinCreERT2+Apcfl/flBrgfl/fl mice
along with VillinCreERT22 controls were induced with four daily
injections of 80 mg/kg Tamoxifen. We sacrificed the mice 4 days
after the first induction and collected samples of the small
intestinal epithelium.
Immunohistochemical analysis of b-catenin and Brg1 expres-
sion in the jejunum epithelium at day 4 post induction revealed
nuclear localisation of b-catenin in both VillinCreERT2+Apcfl/fl and
VillinCreERT2+Apcfl/flBrgfl/fl mice as well as complete loss of Brg1 in
double knock-out animals (Figure 1A). Upon histological inspec-
tion, the small intestinal epithelium of both VillinCreERT2+Apcfl/fl
and VillinCreERT2+Apcfl/flBrgfl/fl mice displayed an aberrant prolif-
erative and apoptotic response synonymous with Wnt pathway
activation [19] (Figure 1A). Although no difference in crypt and
villus length was observed between VillinCreERT2+Apcfl/fl and
VillinCreERT2+Apcfl/flBrgfl/fl mice (Figure 1B, p.0.05, n$4), quan-
titative analysis of other histological parameters such as apoptosis
and mitosis levels as well as 5-bromo-29-deoxyuridine (BrdU)
incorporation 2 hours after a BrdU pulse showed significant
differences between the experimental groups (Figure 1B–1C,
Figure S1A–S1B). Quantification of cleaved Caspase3 positive
cells showed reduced apoptosis in VillinCreERT2+Apcfl/flBrgfl/fl
epithelium (1.8560.51 and 1.060.40 Caspase3 positive cells per
half-crypt, p = 0.04, n = 4, Figure 1B). This observation was
supported by scoring of the number of apoptotic bodies in the
jejunum of VillinCreERT2+Apcfl/fl and VillinCreERT2+Apcfl/flBrgfl/fl
mice (4.0960.34 and 2.6760.45, p,0.01, n$4, Figure S1A).
Quantification of Ki67 positive cells revealed significantly reduced
proliferation in the small intestine of double knock-out mice
compared to their Apc-deficient counterparts (46.18 and 31.91
positive cells per half-crypt, pooled standard deviation 4.54,
p = 0.0004, n$4, Figure 1B). Consistent with this observation,
scoring of BrdU positive cells 2 hours after labelling showed reduced
BrdU incorporation in the jejunum of VillinCreERT2+Apcfl/flBrgfl/fl
mice (32.5166.38 and 23.9160.99, p=0.038, n$4, Figure S1B).
Cumulative distribution analysis of both Ki67 and BrdU positive cells
revealed that the expansion of the proliferative compartment
resulting from Apc deletion was attenuated by additional loss of
Brg1 (Figure 1C and Figure S1C, for all comparisons Kolmogorov-
Smirnov p,0.001).
Interestingly, immunostaining with lysozyme antibody showed a
difference in the distribution of Paneth cells between VillinCreER-
T2+Apcfl/flBrgfl/fl and VillinCreERT2+Apcfl/fl mice. Small intestinal
epithelium of VillinCreERT2+Apcfl/fl animals displayed mislocalisation
of Paneth cells throughout the crypt (Figure 1A, right panels),
consistent with our earlier report of Apc loss [19]. Additional
deletion of Brg1 in VillinCreERT2+Apcfl/flBrgfl/fl mice restored
normal confinement of Paneth cells to the crypt base (Figure 1A,
right panels). Quantitative analysis of Paneth cell number and
position confirmed this observation as both number and
distribution of Paneth cells in VillinCreERT2+Apcfl/flBrgfl/fl epithe-
lium were indistinguishable from normal mucosa (Figure 2A–2B,
for Paneth cell number p= 0.999, for Paneth cell position
Kolmogorov-Smirnov p= 0.17).
Unfortunately, high dose induction resulted in rapid health
deterioration of both VillinCreERT2+Apcfl/flBrgfl/fl and VillinCreERT2+
Apcfl/fl genotypes such that animals had to be killed by 4 days post
induction. We therefore used the in vitro intestinal organoid system
to investigate the fate of double knock-out small intestinal crypts
beyond this time point. VillinCreERT2+Apcfl/fl and VillinCreERT2+
Apcfl/flBrgfl/fl mice along with VillinCreERT22 controls were induced
by 3 daily intraperitoneal injections of 3 mg Tamoxifen and
sacrificed at day 3 post induction. Small intestinal crypts were
isolated and placed in crypt organoid media lacking R-spondin
(crypts from control animals were grown in presence of R-spondin).
By day 6 of culture (day 9 post induction) small intestinal crypts from
control animals became complex organoids (Figure 2C). At the
same time, the majority of VillinCreERT2+Apcfl/fl crypts developed
into large cystic structures (Figure 2C) consistent with a previous
report of organoid culture under Wnt activated conditions [20]. In
contrast, crypts derived from VillinCreERT2+Apcfl/flBrgfl/fl epithelium
rarely developed into large cysts and instead the majority remained
as small simple spherical organoids indicating that double knock-out
crypts had limited proliferative capacity despite constitutive
activation of Wnt signalling (Figure 2C).
Brg1 loss therefore attenuated the histological and physiological
consequences of Apc loss, implicating a compromised Wnt
pathway activity. Notably, we consistently observed fewer cells
with nuclear b-catenin in the epithelium of double knock-out mice
compared to the VillinCreERT2+Apcfl/fl animals. Since nuclear b-
catenin is commonly used as a surrogate marker of b-catenin
activation, we wished to investigate if Brg1 loss suppressed Wnt
signalling upstream of b-catenin activation. Western-blotting
analysis of ‘activated’ b-catenin (dephosphorylated on Ser37 or
Thr41) levels in the intestinal epithelium at day 4 after high-dose
induction did not reveal any differences between the two
experimental groups (Figure 2D), suggesting that Brg1 deficiency
was likely to suppress the Wnt pathway downstream of b-catenin
activation.
In order to further investigate the consequences of Brg1 loss on
theWnt pathway, we assessed expression levels of knownWnt target
genes in the small intestinal epithelium of VillinCreERT2+Apcfl/fl and
double knock-out mice. qRT-PCR analysis of CD44, c-Myc,
CyclinD1 and Ascl2 expression levels revealed significant down-
regulation of these genes in VillinCreERT2+Apcfl/flBrgfl/fl mice
compared to VillinCreERT2+Apcfl/fl epithelium (Figure 2E, p,0.05,
n$3). Notably, we did not observe a significant difference in
expression levels of Axin2, which is commonly used as a readout of
Wnt pathway activation [21], indicating possible differential
recruitment of Brg1 to distinct Wnt target genes.
To further investigate the small intestine-specific role of Brg1 in
the Wnt mediated transcriptional program, we performed
genome-wide expression analysis of Apc-deficient and double
knock-out (DKO) epithelium. VillinCreERT2+Apcfl/fl (n = 3) and
VillinCreERT2+Apcfl/flBrgfl/fl (n = 4) mice along with VillinCreERT22
controls (n = 4) were induced with four daily injections of 80 mg/
Author Summary
Aberrant Wnt signalling is responsible for the majority of
colorectal cancers, the third leading cause of cancer-
related mortality in the UK. However, no therapies directly
targeting Wnt signalling are currently available. Using
mouse models of intestinal cancer, we demonstrate that
deleting chromatin remodelling factor Brg1 in the context
of Apc-deficient small intestinal epithelium attenuates
Wnt-driven gene expression changes and prevents ade-
noma formation, which results in extended animal survival.
We also demonstrate that Brg1 loss impairs the small
intestinal stem cell expansion associated with aberrant
activation of Wnt signalling. These findings highlight Brg1
as a potential therapeutic target in Wnt-driven intestinal
tumourigenesis and illustrate the viability of targeting the
somatic stem cell as the ‘cell of origin’ of cancer, which
might be particularly valuable in patients with known
predisposition to cancer.
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kg Tamoxifen and whole epithelial extract was harvested at day 4
post induction. RNA was extracted from epithelial samples,
labelled and hybridised to Mouse Ref8 v2 Illumina array. To
determine the baseline effect of Brg1 loss, we performed similar
analyses on wild type and induced VillinCreERT2+Brgfl/fl samples,
which are described in our earlier publication [14].
Figure 1. Brg1 loss attenuates the effects of Apc deletion in the small intestinal epithelium. A. H&E, b-catenin and Brg1 staining of the small
intestinal epithelium from control VillinCreERT22, VillinCreERT2+Apcfl/fl and VillinCreERT2+Apcfl/flBrgfl/fl mice 4 days after high-dose induction revealed
disturbed crypt architecture and nuclear localisation of b-catenin in both cohorts, as well as complete loss of Brg1 in VillinCreERT2+Apcfl/flBrgfl/fl
epithelium. Lysozyme immunostaining showed mis-localisation of Paneth cells in VillinCreERT2+Apcfl/fl epithelium, which was restored to normal
by inactivation of Brg1. Scale bars represent 100 mm. B. Scoring of the crypt and villus length revealed no differences between double knock-
out mice (black) and VillinCreERT2+Apcfl/fl animals (grey). Scoring of the cleaved Caspase3 positive cells and Ki67 positive cells detected a
decrease in both apoptosis and proliferation in VillinCreERT2+Apcfl/flBrgfl/fl mice compared to VillinCreERT2+Apcfl/fl animals. Data are shown as
mean 6 group’s standard deviation for Caspase3 quantification and as mean 6 pooled standard deviation otherwise, p value was calculated
by means of t test not assuming equal variance for Caspase3 data and by means of one way ANOVA otherwise, p value was adjusted for
multiple testing. For all comparisons n$4. C. Analysis of cumulative frequency of Ki67 positive cells at each position along crypt-villus axis
revealed expansion of the proliferative compartment in both double knock-out (green line) and VillinCreERT2+Apcfl/fl (orange line) mice
compared to VillinCreERT22 controls (blue line). This expansionwas less pronounced in double knock-outmice compared to VillinCreERT2+Apcfl/fl animals. For
all pair wise comparisons Kolmogorov-Smirnov test p,0.001, n=4.
doi:10.1371/journal.pgen.1004453.g001
Brg1 in Wnt-Driven Intestinal Tumourigenesis
PLOS Genetics | www.plosgenetics.org 3 July 2014 | Volume 10 | Issue 7 | e1004453
Analysis of gene expression betweenWnt activated VillinCreERT2+
Apcfl/fl and control epithelium (APCvsCTR gene set) detected 548
unique differentially expressed ‘Wnt target genes’ including a
number of previously reported Wnt target genes, such as Cd44,
Axin2, Lgr5, Tiam1, Ephb2, Efna4 and Sox9 [22] (Figure 2G, Table
S1) with four of these genes found to be down-regulated in DKO
epithelium compared to Apc-deficient samples (Table S2). Cluster
analysis of genes differentially expressed between Apc-deficient and
Figure 2. Brg1 loss attenuates Wnt target gene expression and prevents mislocalisation of Paneth cells and formation of aberrant
organoids. A. Scoring of the lysozyme positive cells revealed a significant increase in number of Paneth cells in VillinCreERT2+Apcfl/fl (grey bar) mice
compared to double knock-out (black bar) and control (white bar)mice. No difference in Paneth cell numbers was observed between double knock-out and
control epithelium. Data are shown as mean 6 pooled standard deviation, p value was calculated by means of one way ANOVA, n=4. B. Analysis of
cumulative frequency of Paneth cells at each position along crypt-villus axis revealed their expansion into the upper portion of the crypt in
VillinCreERT2+Apcfl/fl epithelium compared to double knock-out and control mice (Kolmogorov-Smirnov test p,0.001, n=4). No difference in Paneth cell
distribution was observed between double knock-out and control epithelium (Kolmogorov-Smirnov test p=0.17, n=4). C. Organoid culture of crypts
derived from VillinCreERT2+Apcfl/fl epithelium produced large cystic organoids by day 6 of culture (day 9 post induction). Meanwhile, very few large cysts
developed from VillinCreERT2+Apcfl/flBrgfl/fl crypts, with most crypts producing compact simple organoids. Crypts from control intestinal epithelium
developed into complex organoid structures by the same time point. Scale bars represent 200 mm. D.Western-blotting analysis of total protein pooled from
3 different animals for each genotype did not reveal changes in the levels of activated b-catenin between VillinCreERT2+Apcfl/fl and VillinCreERT2+Apcfl/flBrgfl/fl
epithelial samples. Substantially weaker signal was detected in the samples from VillinCreERT22 control animals. E. qRT-PCR analysis of total RNA extracted
from the small intestinal epithelium revealed significantly increased expression of b-catenin and a range of Wnt target genes in VillinCreERT2+Apcfl/fl (grey
bars) and VillinCreERT2+Apcfl/flBrgfl/fl (black bars) samples compared to control VillinCreERT22 (white bars) animals. Expression levels of c-Myc, CD44, CyclinD1
and Ascl2, but not b-catenin or Axin2 genes were found to be significantly lower in double knock-out epithelium compared to VillinCreERT2+Apcfl/fl samples.
Mann-Whitney U-test was performed on DDCt values, * - p,0.05, n$4. F. Clustering analysis of genes differentially expressed between VillinCreERT2+Apcfl/fl
and VillinCreERT22 control epithelium revealed that the same genes in VillinCreERT2+Apcfl/flBrgfl/fl epithelium largely assumed intermediate expression values
between those of the other two groups. G. Venn diagram demonstrating overlap between pairwise comparisons of differentially expressed gene signatures
within various cohorts.
doi:10.1371/journal.pgen.1004453.g002
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control epithelium revealed clustering of DKO mice with control
samples (Figure 2F), indicating a greater similarity of the gene
expression pattern between DKO and wild type samples compared
to Apc-deficient intestine. Notably, the majority of gene expression
values from DKO samples were intermediate between those of
VillinCreERT2+Apcfl/fl and control samples (Figure 2F), indicating
attenuation of the Wnt pathway transcriptional signature regardless
of whether Wnt activation induced or suppressed gene expression.
We also observed a strong negative correlation pattern when
directions of gene expression changes between Apc-deficient and
wild type epithelium were contrasted with changes between double
knock-out and Apc-deficient mice (Figure S2A, r=20.793, p,
0.0001).
In order to evaluate how many Wnt target genes were
attenuated by additional Brg1 loss we compared the overlap
between the sets of differentially expressed genes (Figure 2G). We
identified 197 unique differentially expressed genes between
VillinCreERT2+Apcfl/fl and VillinCreERT2+Apcfl/flBrgfl/fl samples
(DKOvsAPC set) (Table S2). Of these, half (99/197) appeared
to be ‘Wnt targets’ defined as those present in APCvsCTR gene set
(Figure 2G, Table S1), representing 18% (99/548) of the total
number of genes that were deregulated following Apc loss (Table
S4, Figure 2G). Since Brg1 loss was able to significantly attenuate
deregulation of these Wnt targets, these genes could be designated
as ‘highly dependent on Brg1’ (Table S7). Comparison of gene
expression between VillinCreERT2+Apcfl/flBrgfl/fl and control sam-
ples (DKOvsCTR gene set) identified 200 unique differentially
expressed genes (Figure 2G, Table S3). Comparison of this gene
set to the APCvsCTR set revealed that 16% (87/548) of ‘Wnt
target genes’ were present in both sets, but not in the DKOvsAPC
set (Table S5). Since Brg1 loss failed to attenuate deregulation of
these genes, they could be considered as ‘Brg1 independent Wnt
targets’ (Table S7). Notably, Brg1 deficiency in double knock-out
samples prevented deregulation of 84% (458/548) of Wnt target
genes from their expression levels in control intestine. With the
exception of the 99 highly Brg1 dependent Wnt targets these 66%
(362/548) of genes could be designated as ‘Wnt targets with low
Brg1 dependency’ (Table S7). This gene subset included such Wnt
targets as Axin2, Ephb2 and Sox9. Overall, these data indicated that
up to 84% of all Wnt target genes in the small intestinal epithelium
are dependent to some extent on Brg1 for either their activation or
suppression.
It could be argued that gene expression changes upon
additional deletion of Brg1 in the Apc-deficient epithelium
could arise from the global effect of Brg1 loss on gene expression
rather than its specific relevance for the Wnt-driven transcrip-
tional programme. To address this caveat we also analysed the
genes differentially expressed between Brg1-deficient and wild
type epithelium. Despite a drastic effect on epithelial homeo-
stasis, Brg1 loss induced a relatively moderate perturbation in
gene expression at day 4 post induction with 86 genes
differentially expressed between Brg1-deficient and control
epithelium (Table S8) [14]. Expectedly, a small proportion of
the genes differentially expressed between Apc-deficient and
double knock-out samples were also de-regulated between Brg1-
deficient and wild type epithelium (23/197 genes (11.7%) Table
S9, Figure S2B). This proportion was notably lower when Brg1
targets were compared to the list of Wnt targets with high Brg1
dependency (5/99 genes (5.1%), Table S9). Together, these
observations strongly suggested that gene expression changes
following Brg1 loss in the context of Apc deficiency were largely
a result of a specific effect of Brg1 deficiency on the Wnt
pathway transcriptional programme rather than an impact of
Brg1 deletion on global gene expression.
16 genes which overlapped between the DKOvsCTR and
DKOvsAPC sets (Table S6, Figure 2G) appeared deregulated by
Brg1 deficiency regardless of Wnt activation and therefore most
likely represented direct Brg1 targets independent of Wnt
signalling. Most of these genes (11/16) were also present among
genes differentially expressed between Brg1-deficient and control
samples (Table S9, Figure S2C) [14].
Notably, one of the Wnt targets, whose expression was
attenuated following additional loss of Brg1, was the proposed
intestinal stem cell marker Lgr5 [23]. We therefore decided to
explore the effects of Apc deletion and subsequent Brg1 loss on the
expression of genes associated with the intestinal stem cell
compartment. To this end we compared gene expression changes
between our cohorts to the extensive stem cell signature. Using 3
distinct genome-wide expression platforms Mun˜oz et al. identified
510 genes that were preferentially expressed in the murine small
intestinal Lgr5high cells [24]. We identified 460 of these stem cell-
specific genes in our array, which corresponded to 721 probes
(Table S10).
We then employed ROAST function [25] from the limma
Bioconductor package [26] to determine if stem cell-specific genes
were enriched among genes differentially expressed between our
cohorts. Consistent with the reported stem cell expansion following
aberrant activation of Wnt signalling [27–29], 50.5% of stem cell-
specific genes were found to be up-regulated in VillinCreERT2+
Apcfl/fl mice compared to the control cohort (p,0.0001). Double
knock-out epithelium also displayed increased expression of stem
cell-related genes compared to control samples, however only in
32.3% of genes (p = 0.0002). In contrast, 41.2% of all stem cell
genes were suppressed in double knock-out epithelium compared
to VillinCreERT2+Apcfl/fl mice (p,0.0001).
We also queried sets of differentially expressed genes between
our cohorts for the presence of stem cell-specific genes. While this
approach was less sensitive than using ROAST function, we
observed a substantial number of stem cell signature genes in our
differentially expressed gene sets (Tables S11, S12, S13). In line
with the proposed Wnt-driven stem cell expansion [27–29], 10.6%
(58/548) of all genes differentially expressed upon Apc deletion
were found to belong to the stem cell signature. Of these 98% (57/
58) were found to be up-regulated. In contrast, genes differentially
expressed between double knock-out and Apc-deficient intestine
contained 11.2% (22/197) of genes from the stem cell signature, all
of which were down-regulated (Tables S11, S12, S13). Similar to
the pattern of gene expression changes across all genes, stem cell
related genes displayed strong negative correlation, when expres-
sion changes between Apc-deficient and wild type epithelium were
contrasted with ones between double knock-out and Wnt activated
intestine (Figure S2D, r=20.859, p,0.0001).
Notably, the proposed Wnt-independent intestinal stem cell
marker Olfm4 [27] was found to be down regulated in the double
knock-out intestine when compared to both Apc-deficient and
normal epithelium, indicating strong Brg1 control over Olfm4
expression.
Brg1 loss prevents Wnt-driven adenoma formation in the
context of the murine small intestinal epithelium
The apparent requirement of Brg1 for the expression of Wnt
target genes following aberrant Wnt activation in the small
intestinal epithelium raises the possibility that Brg1 loss may also
prevent Wnt-driven tumour development. To explore this
possibility we assessed the effects of Brg1 loss on Wnt-driven
adenoma formation by driving recombination of the floxed Apc
and Brg1 alleles with the Tg(Cyp1a1-cre/ESR1)1Dwi transgene,
further abbreviated as AhCreERT [30]. This transgene encodes
Brg1 in Wnt-Driven Intestinal Tumourigenesis
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Cre-ERT recombinase under the control of the Cyp1A promoter.
In contrast to VillinCreERT2 recombinase, which is expressed in the
entirety of the intestinal epithelium, AhCreERT transgene’s
expression is confined to the stem cell and early progenitor
compartments. Additionally, AhCreERT recombinase requires
exposure to both b-naphthoflavone and tamoxifen for its
activation, which results in tighter control over its activity. We
used this approach to inactivate Apc and Brg1 in the small
intestinal epithelium at a lower frequency than above, thus
extending animal survival and enabling us to analyse the long-term
effects of Brg1 loss on Wnt-driven adenoma formation.
We induced 3 cohorts of mice (AhCreERT2 controls, AhCreERT+
Apcfl/fl and AhCreERT+Apcfl/flBrgfl/fl) with 5 bi-daily intraperitoneal
injections of 80 mg/kg of b-naphthoflavone and 80 mg/kg of
tamoxifen. Animals were aged and sacrificed either at day 10 post
induction (n= 4) or when they displayed signs of terminal illness (n$
20).
Immunohistochemical analysis of b-catenin localisation in the
small intestinal epithelium at day 10 revealed multiple aberrant
foci with nuclear b-catenin in both AhCreERT+Apcfl/fl and double
knock-out mice, indicating successful activation of the Wnt
pathway in those lesions (Figure 3A, left and central). At the
same time, Brg1 immunostaining revealed clusters of Brg1
negative cells in AhCreERT+Apcfl/flBrgfl/fl intestinal epithelium
(Figure 3A, right). In contrast to the small intestine of
VillinCreERT2+Apcfl/flBrgfl/fl mice, where the majority of cells after
induction were deficient for Brg1 and displayed nuclear localisa-
tion of b-catenin, all the lesions with nuclear b-catenin in the
AhCreERT+Apcfl/flBrgfl/fl intestine were Brg1-positive and we failed
to detect any overlap between Brg1-deficient clusters and Wnt-
activated lesions (Figure 3A, central and right). This observation
suggested that, when driven by AhCreERT recombinase, Brg1 loss
was incompatible with long term activation of the Wnt pathway
and the development of aberrant crypt foci, consistent with
inability of crypts from double knock-out epithelium to form
aberrant organoids in vitro (Figure 2C).
Analysis of the ageing cohorts revealed that combined deletion of
Apc and Brg1 deletion provided a survival advantage in comparison
to single Apc deletion (Figure 3B). Whilst all the AhCreERT+Apcfl/fl
mice became terminally ill within 20 days post induction (median
survival 9 days), the majority of AhCreERT+Apcfl/flBrgfl/fl mice
survived substantially longer (median survival 58 days) with some
mice surviving past 100 days (Figure 3B, Log-rank test p,0.0001,
n$20 for each cohort). No control animals (n= 8) developed signs of
ill health within the timeframe of the experiment.
Histological inspection of the small intestine of the AhCreERT+
Apcfl/flBrgfl/fl mice at late time points revealed numerous small
lesions confined within the distended villi and identified as micro-
adenomas (Figure 3C), as well as rare large adenomas. Immuno-
histochemical analysis of b-catenin expression showed that all of
these lesions were positive for nuclear b-catenin, confirming
aberrant Wnt signalling activation (Figure 3C, left). Notably, Brg1
staining demonstrated that all the lesions retained Brg1 expression
(Figure 3C, right), indicating that they were likely to originate from
cells that recombined at the Apc, but not at the Brg1 loci. Along with
the apparent lack of double mutant lesions at day 10 post induction,
this indicated that long-term progression of Wnt-driven neoplasia in
the small intestine was incompatible with Brg1 deficiency. We
therefore explored the possibility that Brg1 loss in the context of
activated Wnt signalling could reduce tumour burden and thus
improve animal survival. We induced AhCreERT+Apcfl/fl and
AhCreERT+Apcfl/flBrgfl/fl mice with two bi-daily injections of
80 mg/kg b-naphthoflavone and 80 mg/kg tamoxifen to achieve
attenuated recombination and harvested the small intestinal
epithelium at day 40 post induction. We then scored the number
of lesions with nuclear b-catenin normalised to the number of
normal crypt units contained within the analysed region of the small
intestinal epithelium. Quantitative analysis of the tumour burden
from two independent experiments revealed a 2.92-fold decrease in
the number of lesions in the double knock-out small intestinal
epithelium compared to AhCreERT+Apcfl/fl animals (p= 0.026, n$5)
indicating reduced tumour burden upon Brg1 loss.
Stem cell-restricted Brg1 loss suppressed Wnt-driven
tumourigenesis
Prevalence of micro-adenomas and lack of advanced adenomas
in the small intestines of the AhCreERT+Apcfl/flBrgfl/fl mice as late as
100 days post induction indicated that this genetic environment
favoured the development of lesions with a limited growth
potential. Barker et al. [28] suggested that adenomas originating
from intestinal stem cells had a higher tumourigenic potential
compared to those derived from transit amplifying cells. To test
whether stem cell-specific Brg1 loss could attenuate Wnt-driven
adenoma formation we intercrossed mice expressing the GFP-
IRES-CreERT2 knock-in allele under control of the Lgr5 promoter
(further abbreviated as Lgr5-GFP-CreERT2) [23] with animals
Figure 3. Brg1 loss is incompatible with Wnt-driven adenoma
formation and improves animal survival upon Apc inactivation
in the small intestine. A. Immunohistochemical analysis of b-catenin
revealed numerous lesions with nuclear localisation of b-catenin in the
small intestine of AhCreERT+Apcfl/fl and AhCreERT+Apcfl/flBrgfl/fl mice 10
days post induction. Brg1 immunostaining of serial sections showed
clusters of Brg1-deficient cells in AhCreERT+Apcfl/flBrgfl/fl intestine, but
failed to detect any overlap between lesions with nuclear b-catenin and
Brg1 negative cells. B. Survival analysis demonstrated significantly
increased survival probability of AhCreERT+Apcfl/flBrgfl/fl mice (blue line,
median survival 58 days) compared to AhCreERT+Apcfl/fl animals (green
line, median survival 9 days). Log-rank test p,0.0001, n$20. No control
animals died within the timeframe of the experiment (n= 8). C. b-catenin
immunostaining of the small intestinal epithelium of AhCreERT+Apcfl/fl
Brgfl/fl mice 100 days post induction revealed numerous micro adenomas
enclosed within distended villi. Staining with Brg1 antibody showed that
all the micro adenomas retained Brg1 expression. Scale bars represent
100 mm (A) and 200 mm (B).
doi:10.1371/journal.pgen.1004453.g003
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bearing targeted Apc and Brg1 alleles. Lgr5-GFP-CreERT2+Apcfl/fl
and Lgr5-GFP-CreERT2+Apcfl/flBrgfl/fl mice were induced with four
daily intraperitoneal injections of tamoxifen (initial dose of 3 mg
was followed by three doses of 2 mg). Animals were aged for 420
days after induction or until they developed signs of ill health.
Survival analysis of the cohorts revealed a substantial increase in
survival of double knock-out mice compared to their Lgr5-GFP-
CreERT2+Apcfl/fl counterparts (median survival 344 and 110 days
post induction respectively, Figure 4A, Log-rank p,0.001, n= 14
for each cohort).
Immunohistochemical analysis of b-catenin expression in the
small intestine of both Lgr5-GFP-CreERT2+Apcfl/fl and Lgr5-GFP-
CreERT2+Apcfl/flBrgfl/fl mice revealed a mixture of micro and
macro-adenomas with nuclear b-catenin at a range of time points
(Figure 4B). Immunohistochemical analysis of GFP expression in
small intestinal tumours detected GFP positive cells in both macro
and micro adenomas, implying activity of the Lgr5-GFP-CreERT2
transgene and stem cell origin of both types of lesions (Figure 4B).
This observation suggested that not all stem cell-derived adenomas
were able to progress to advanced stages. Equally, we observed
numerous micro adenomas devoid of GFP expression (not shown).
These lesions were likely to arise from early progenitor cells, which
might have lost self renewal ability, but retained some Cre-ERT2
recombinase expression.
Similar to the pattern observed in the small intestine of
AhCreERT+Apcfl/flBrgfl/fl mice, adenomas in the small intestine of
Lgr5-GFP-CreERT2+Apcfl/flBrgfl/fl mice retained Brg1 expression
(Figure 4B) providing further support to the notion that Brg1 loss
is incompatible with Wnt-driven adenoma formation.
Discussion
Brg1 acts as a positive regulator of Wnt signalling and is
required for Wnt-driven adenoma formation in the small
intestinal epithelium
We have demonstrated that inactivation of Brg1 resulted in
reduced expression of Wnt target genes following activation of the
canonical Wnt pathway via Apc deletion in the small intestinal
epithelium. A number of studies have previously suggested that
Brg1 facilitates trans-activation of Wnt target genes by activated b-
catenin in cancer cell lines [12,13], zebrafish [31] and during
mammalian vascular development [32]. Our study provides the
first evidence of the functional interaction between Brg1 and the
Wnt pathway in the context of intestinal tumourigenesis using an
in vivo system. Using transcriptome analysis, we identified sets of
Wnt target genes which displayed differing levels of dependency
on Brg1 function. Overall, we identified 548 genes that were
deregulated upon Apc deletion in the small intestinal epithelium.
Of these, 87 genes were Brg1 independent and 461 displayed a
variable degree of dependency on Brg1 function, indicating that
deregulation of the majority (85%) of Wnt responsive genes in the
small intestinal epithelium depended (to differing degrees) on the
presence of functional Brg1. This observation is in line with a
previous report, which found a similar proportion (68%) of Wnt
targets to rely on Brg1 for their response to Wnt activation in the
HEK293T cell line [33].
Consistent with the requirement for Brg1 in the maintenance of
the small intestinal stem cell population [14], we observed
attenuated expression in a range of genes associated with the
small intestinal stem cells following Brg1 loss in the context of
aberrantly activated Wnt signalling. These genes included
functionally validated stem cell markers such as Lgr5, Ascl2 and
Olfm4, suggesting that Brg1 loss was able to impair the expansion
of the ‘stem-like’ cell population characteristic of Wnt-driven
intestinal tumourigenesis [27–29]. Furthermore, expression levels
of Olfm4 in the small intestine of double knock-out mice were
lower compared to that in both wild type and Apc-deficient
epithelium, strongly suggesting a role of Brg1 in regulation of
Olfm4 expression. Olfm4 is a secreted anti-apoptotic factor,
which has been reported to be over-expressed in a variety of
tumours [34]. Depletion of Olfm4 in gastric cancer cells has been
reported to suppress proliferation and sensitise cancer cells to
apoptosis [35,36]. Olfm4 thus constitutes a potentially attractive
therapeutic target, especially so in view of its secreted nature,
which makes it a feasible target for monoclonal antibody
therapies.
In addition to suppression of Wnt target genes, Brg1 loss also
attenuated the physiological manifestations of Wnt activation in
the intestinal epithelium, most notably the increased cell
proliferation and mislocalisation of Paneth cells. Both Paneth
cell quantity and position were restored to normal levels in the
double knock-out epithelium, suggesting that Brg1 deletion was
able to preserve physiological levels of EphB/Ephrin signalling
in the context of Apc deficiency [37]. Consistent with this
Figure 4. Stem cell-specific Brg1 loss in the small intestine
attenuates Wnt-driven adenoma formation and improves
animal survival. A. Survival analysis demonstrated significantly
increased survival of Lgr5-GFP-CreERT2+Apcfl/flBrgfl/fl mice (median survival
344 days post induction) compared to Lgr5-GFP-CreERT2+Apcfl/fl animals
(median survival 110 days). Log-rank test p,0.0001, n=14. B. b-catenin
immunostaining detected micro and macro adenomas with nuclear b-
catenin in the distal small intestinal epithelium of Lgr5-GFP-CreERT2+Apcfl/fl
and Lgr5-GFP-CreERT2+Apcfl/flBrgfl/fl mice at various time points. Both types
of lesions were found to express GFP and Brg1 indicating their stem cell
origin and selective elimination of Brg1-deficient tumours. Scale bars
represent 100 mm.
doi:10.1371/journal.pgen.1004453.g004
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notion, our transcriptome analysis detected up-regulation of
EphB2 expression in Apc-deficient intestine, but not in double
knock-out epithelium, when compared to control samples. A
similar effect of Wnt signalling attenuation on the Paneth cell
mislocalisation has been previously demonstrated following loss
of Mbd2 in the Apc-deficient small intestine [38]. Given the
proposed role for Paneth cells as the intestinal stem cell niche
[20], this effect of Brg1 loss on Paneth cell mislocalisation could
contribute to the attenuated stem cell expansion in double
knock-out intestine.
In the view of extensive role of Wnt signalling in tumourigen-
esis [1], Brg1 mediated modulation of the Wnt pathway may
have implications for the development of novel therapeutic
approaches. Here we report that loss of Brg1 in the context of Apc
deletion improved animal survival by preventing the formation of
double mutant adenomas. All adenomas observed in the small
intestine of double knock-out mice retained Brg1 expression
indicative of their origin from cells that had lost Apc but had
escaped Brg1 deletion. This implies an absolute requirement of
functional Brg1 for Wnt-mediated tumourigenesis in this tissue. A
similar relationship between Brg1 inactivation and a loss of
tumour suppressor Snf5 (Ini1) has been reported by Wang et al.
[39]. Simultaneous inactivation of Brg1 and Snf5 under control of
the T-cell lineage-specific Lck-Cre recombinase resulted in
decreased tumour incidence and a longer disease onset. Similar
to our observations, all the Snf5-deficient tumours, which
developed in double-mutant animals, retained Brg1 expression
[39].
Barker et al. [28] suggested a particular role for intestinal stem
cells in Wnt-driven tumour initiation with non-stem cells giving
rise to adenomas with limited growth capacity, while stem cell
gene signature in human primary colorectal cancers was found to
be associated with more aggressive phenotype [40]. In a similar
fashion, Alcantara Llaguno et al. [41] reported neural stem cells as
the cell of origin for malignant gliomas. Furthermore, a recent
study has demonstrated a substantial survival advantage of genetic
targeting of glioblastoma cancer stem cells using a neural stem cell
marker Nestin [42]. Consistent with these reports, and in line with
negative impact of Brg1 loss on long-term small intestinal stem cell
survival, we observed a markedly improved survival upon stem
cell-specific Brg1 deletion in the context of aberrant Wnt
activation. Notably, the above study made use of stem cell-specific
expression of the toxic thymidine kinase transgene to target the
sub-population of cancer cells bearing normal stem cell markers
[42]. In contrast to this, we report successful tumour suppression
by targeting a gene required for the physiological small intestinal
stem cell maintenance, a relationship, which to our knowledge has
not been previously reported. It should be noted that mice with
stem cell-specific Apc loss alone in the present report exhibited
longer survival times compared to those in the study by Barker et
al. [28], which could be attributed to increased levels of silencing of
the Lgr5-GFP-CreERT2 transgene in our mice. Tumours in the
small intestine of animals bearing the Lgr5-GFP-CreERT2 transgene
and targeted Apc alleles were mainly detected in the distal third of
the small intestine with fewer lesions in the proximal part and very
few tumours in between. Given that biallelic Apc deletion would
fall within ‘high pathological Wnt’ scenario described in Leedham
et al. [43], this tumour distribution was consistent with the
gradient of the Wnt signal and stem cell density in the murine
intestine.
It should be noted that given the concurrency of Brg1 and
Apc deletion, results presented in this report pertain to cancer
prevention rather than therapy. Additionally, Brg1 loss-driven
elimination of intestinal stem cells is likely to be a major
contributing factor to attenuated tumour burden in double
knock-out mice and may therefore obscure the effects of Brg1
deletion on non-stem tumour cells. Importantly, this toxicity of
Brg1 loss in respect to the small intestinal stem cell homeostasis
constitutes a potential serious caveat to the use of Brg1 as a
therapeutic target. However our data from the previous report
[14] as well as from AhCreERT+Apcfl/flBrgfl/fl and Lgr5-GFP-
CreERT2+Apcfl/flBrgfl/fl models in the present study demonstrate
that partial Brg1 loss is well tolerated by the small intestinal
epithelium, which is gradually repopulated with wild type cells.
At the same time, partial loss of Brg1 was sufficient to reduce
the tumour burden, suggesting that a therapeutic window may
exist that would allow targeting Brg1 in the intestinal polyps,
while allowing repopulation of the normal intestinal epitheli-
um. A strategy that would allow for the efficient Brg1
deletion in existing adenomas or the use of a Brg1
inhibitor would be required to further address the effects of
Brg1 in non-stem cell portion of established Wnt-driven
tumours, as well as the potential therapeutic window of
targeting Brg1.
In summary, we demonstrate using mouse models of intestinal
cancer that Brg1 is essential for Wnt-driven tumourigenesis in
the murine small intestine with attenuation of Wnt target gene
expression and elimination of transformed stem cells as two
likely mechanisms. Brg1 therefore constitutes a potential
therapeutic target in cancers with an aberrantly activated Wnt
pathway. Combined with our earlier observation that Brg1 is
essential for stem cell maintenance in the small intestinal
epithelium under the physiological conditions, these data may
serve as a proof of concept that targeting the somatic stem cell
as a cancer initiating cell may provide a valuable therapeutic
approach, especially in the context of predisposition to Wnt-
driven carcinogenesis, such as in Familial Adenomatous
Polyposis patients.
Materials and Methods
Experimental animals
All experiments were carried out in accordance with Animals
(Scientific Procedures) Act 1986 under project licenses 30/2246
and 30/2737 issued by UK Home Office. The study was approved
by the Cardiff University Research Ethics Committee. Mice were
maintained on an outbred background and genotyped as
described previously for targeted Apc allele [15], Cre-ERT and
Cre-ERT2 transgenes [19], targeted Brg1 allele [16]. Detailed
induction protocols and dissection procedures are described in
Text S1.
Histological procedures
Detailed description of protocols for tissue fixation, processing,
immunohistochemistry, and quantitative analysis of tissue sections
is available in Text S1.
Statistical analysis of histological data
All statistical tests except survival and cumulative distribution
analyses were carried out using R software [44]. Scoring data were
tested for normality using Shapiro-Wilk test and for equal variance
using Levene’s test. Normally distributed data with equal variance
were tested for difference between means using one-way ANOVA.
Where appropriate, p values were adjusted for multiple testing
using TukeyHSD function in R. In cases of unequal variance
between groups the difference between those groups was tested
using t-test not assuming equal variance. Unless otherwise
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specified, pooled standard deviation from one-way ANOVA was
used to represent error bars. Positional data were analysed for
differences in distribution with Kolmogorov-Smirnov Z-test in
SPSS (version 16.0.2). Kaplan-Meier survival curve and Log-rank
survival analysis were carried out using GraphPad Prism (version
6).
RNA extraction, quantitative RT-PCR and microarray
analysis
Detailed description of the protocols and statistical methods
used for RNA extraction, qRT-PCR and transcriptome analysis is
available in Text S1. Microarray analysis was carried out using
beadarray [45] and limma [26] packages from Bioconductor
project. Microarray data for the study are publicly available from
the GEO repository (http://www.ncbi.nlm.nih.gov/geo) under
the series record GSE46129.
Protein extraction and western blot analysis
A detailed protocol for obtaining epithelial-enriched popu-
lation of cells for protein extraction and western-blotting is
provided in Text S1. Protein was extracted from the epithe-
lium-enriched small intestinal samples, separated, transferred
and probed as described previously [46]. The primary
antibodies used: mouse anti-active b-catenin (1:2000; Millipore)
and mouse anti-b-actin (1:5000; Sigma). Anti-mouse horserad-
ish peroxidase conjugated secondary antibody (1:3000; GE
Healthcare) and ECL or ECL Plus reagents (Amersham
Biosciences) were used to detect the signal according to the
manufacturer’s manual.
In vitro organoid culture
Small intestinal crypts from VillinCreERT22 controls, Villin-
CreERT2+Apcfl/fl and VillinCreERT2+Apcfl/flBrgfl/fl mice were isolated
and cultured as described in Sato et al. [47] with minor
adjustments. Detailed procedures are described in Text S1.
Supporting Information
Figure S1 Brg1 loss attenuates Wnt-driven apoptosis and cell
proliferation in the small intestinal epithelium. (A, B) Scoring of the
apoptotic bodies (A) and BrdU positive cells 2 hours post labelling (B)
showed significantly reduced apoptosis levels and BrdU incorporation
in VillinCreERT+Apcfl/flBrgfl/fl mice compared to VillinCreERT+Apcfl/fl
animals. Graphs are represented as mean 6 group-wise standard
deviation. Difference between means was tested by means of t-test for
samples with unequal variance and adjusted for multiple testing. (C)
Analysis of cumulative frequency of BrdU positive cells at each cell
position along crypt-villus axis 2 hours after labelling revealed
significant expansion of BrdU positive cells in VillinCreERT+Apcfl/
flBrgfl/fl (green line) and VillinCreERT+Apcfl/fl (orange line) mice
compared to VillinCreERT2 controls. This expansion was less
pronounced in epithelium of VillinCreERT+Apcfl/flBrgfl/fl mice com-
pared to VillinCreERT+Apcfl/fl animals. For all comparisons Kolmo-
gorov-Smirnov test p,0.001, n=4.
(TIF)
Figure S2 Brg1 deletion specifically reverses gene expression
changes induced by Apc deletion. (A, D) Correlation analysis of
changes in gene expression revealed a strong negative correlation
in expression patterns of genes in Apc deficient and double knock-
out epithelium. The same pattern was observed for genome-wide
analysis (A) and when applied to the genes from intestinal stem cell
signature (D). Biological correlation is distinguished from technical
correlation using ‘‘genas’’ function from Limma Bioconductor
package [26]. (B) Genes deregulated by Brg1 loss in the control
epithelium comprised a small fraction of genes affected by Brg1
deletion in the context of Apc loss (5/99 genes). (C) A small set of
16 genes that were disrupted by Brg1 loss regardless of Apc
deletion were largely represented by direct Brg1 targets and were
also misexpressed following Brg1 loss in normal intestinal
epithelium (11/16 genes).
(TIF)
Table S1 Genes differentially expressed between VillinCre+Apcfl/fl
and VillinCre2 small intestinal epithelium.
(XLS)
Table S2 Genes differentially expressed between VillinCre+Apcfl/
flBrgfl/fl and VillinCre+Apcfl/fl small intestinal epithelium.
(XLS)
Table S3 Genes differentially expressed between VillinCre+
Apcfl/flBrgfl/fl and VillinCre2 small intestinal epithelium.
(XLS)
Table S4 Overlapping and exclusive differentially expressed
genes between VillinCre+Apcfl/fl vs VillinCre2 (APCvsCTR) and
VillinCre+Apcfl/fl vs VillinCre+Apcfl/flBrgfl/fl (DKOvsAPC) datasets.
Colours correspond to the colours in venn diagram in Figure 2G.
(XLS)
Table S5 Overlapping and exclusive differentially expressed
genes between VillinCre+Apcfl/fl vs VillinCre2 (APCvsCTR) and
VillinCre+Apcfl/flBrgfl/fl vs VillinCre2 (DKOvsCTR) datasets. Colours
correspond to the colours in venn diagram in Figure 2G.
(XLSX)
Table S6 Overlapping and exclusive differentially expressed
genes between VillinCre+Apcfl/flBrgfl/fl vs VillinCre2 (DKOvsCTR)
and VillinCre+Apcfl/fl vs VillinCre+Apcfl/flBrgfl/fl (DKOvsAPC) data-
sets. Colours correspond to the colours in venn diagram in
Figure 2G.
(XLS)
Table S7 Wnt target gene sets with differing levels of Brg1
dependency. Colours correspond to the colours in venn diagram in
Figure 2G.
(XLS)
Table S8 Genes differentially expressed between VillinCre+
Brg1fl/fl and VillinCre2 small intestinal epithelium.
(XLS)
Table S9 Overlap of Brg1 targets (VillinCre+Brg1fl/fl vs VillinCre2)
and differentially expressed genes in various gene sets. Colours
correspond to the colours in venn diagram in Figure 2G.
(XLS)
Table S10 Small intestinal stem cell specific gene signature from
Mun˜oz et al., (2012). Genes not detected in our array are
highlighted in red.
(XLS)
Table S11 Stem cell signature genes differentially expressed
between VillinCre+Apcfl/fl and VillinCre2 small intestinal epithelium.
(XLS)
Table S12 Stem cell signature genes differentially expressed be-
tween VillinCre+Apcfl/flBrgfl/fl and VillinCre2 small intestinal epithelium.
(XLS)
Table S13 Stem cell signature genes differentially expressed
between VillinCre+Apcfl/flBrgfl/fl and VillinCre+Apcfl/fl small intestinal
epithelium.
(XLS)
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Table S14 Primers used for qRT-PCR analysis.
(XLS)
Text S1 Extended materials and methods.
(DOC)
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